ALKERMES | ALKS - Debt


ALKERMES reported $72.68M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
ALKERMES USD 72.68M 293.32M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 309.5M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Malin Corporation EUR 100K 0 Dec/2023
Merck USD 41.37B 5.97B Sep/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Otsuka Holdings JPY 252.7B 63.32B Mar/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025